Clinical Trial Detail

NCT ID NCT02970318
Title A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

chronic lymphocytic leukemia

Therapies

Bendamustine + Idelalisib + Rituximab

Acalabrutinib

Age Groups: adult senior

No variant requirements are available.